On December 17, 2021, Karyopharm Therapeutics Inc. (the "Company") reported that it entered into a License Agreement (the "Agreement") with Berlin-Chemie AG, an affiliate of the Menarini Group ("Menarini"), pursuant to which the Company granted Menarini a non-exclusive license to develop, and an exclusive license to commercialize, products containing selinexor, the Company’s lead Selective Inhibitor of Nuclear Export ("SINE") compound (the "Product"), for all human oncology indications in the European Economic Area, United Kingdom, Switzerland, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Uzbekistan, Ukraine, Turkey, Mexico, all Central America countries and all South America countries (collectively, the "Territory") (Filing, 8-K, Karyopharm, DEC 17, 2021, View Source [SID1234597532]). In addition, the Company granted to Menarini a non-exclusive license to package and label the Product in or outside of the Territory for all human oncology indications solely to enable Menarini to commercialize the Product within the Territory.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the Agreement, the Company will use commercially reasonable efforts to develop the Product, transfer any marketing approval or authorization with respect to the Product in the Territory to Menarini and to complete any post-marketing approval or authorization studies required by a regulatory authority as a condition of maintaining the approval in any country in the Territory (the "Post-Registration Studies"). Menarini is obligated to use commercially reasonable efforts to apply for and obtain marketing approval or authorization of the Product, and to obtain price or reimbursement approval for the Product after approval of the relevant marketing approval or authorization, in each country of the Territory in each indication for which the Company has conducted a registrational clinical trial. Menarini is also obligated to use commercially reasonable efforts at its sole cost and expense to launch and commercialize the Product in each country of the Territory in each indication for which the Company has conducted a registrational clinical trial.
The Company will receive an upfront cash payment of $75.0 million in 2021, which we believe will extend the Company’s cash runway to early 2024. The Company is also entitled to receive up to $202.5 million in milestone payments from Menarini if certain development and sales performance milestones are achieved. The Company is further eligible to receive tiered royalties ranging from the mid-teens to mid-twenties based on future net sales of the Product in the Territory. The payments owed by Menarini to the Company are subject to reduction in specified circumstances. Menarini will reimburse the Company for 25% of all documented expenses incurred by the Company for the global development of the Product during 2022 through 2025, provided that such reimbursements shall not exceed $15.0 million per calendar year.
Menarini will purchase Product from the Company in accordance with a supply agreement to be entered into by the Company and Menarini (the "Supply Agreement"). The Company will supply all required quantities of selinexor and Product for the Territory as set forth in the Supply Agreement.
The development and commercialization of the Product for all human oncology indications in the Territory as contemplated by the Agreement will be subject to oversight by a joint steering committee composed of employees of the Company and Menarini, with the Company having final decision-making authority with regard to the development of the Product, as well as certain other technical, scientific and clinical operations matters, and Menarini having final decision-making authority with regard to the commercialization of the Product. Each party has also agreed to indemnify the other party from certain liabilities specified in the Agreement.
The Agreement will continue in effect on a country-by-country basis until the last to occur among: (i) the fifteenth anniversary of the first commercial sale of the Product in the applicable country, (ii) the expiration of the last-to-expire of the licensed patent rights in the applicable country or (iii) the expiration of any regulatory exclusivity protection covering the Product in such country. However, the Agreement may be terminated earlier by either party for (i) an uncured material breach of the Agreement by the other party (A) on a country-by-country basis with respect to the country to which the breach
relates if the breach is specific to such country and does not affect the Agreement as a whole or (B) in its entirety if the breach affects the Agreement as a whole, or (ii) in the event of the insolvency or bankruptcy of the other party. The Company may terminate the Agreement for certain patent challenges by Menarini.
The Company expects to file the Agreement as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2021. The foregoing is a description of certain terms